Filing Flows › Akebia Therapeutics (AKBA) › Capital expenditures
Akebia Therapeutics (AKBA) capital expenditures by quarter
Akebia Therapeutics' capital expenditures were $706K in Q3 2026 (third quarter 2026), -35% from Q2 2026. Over the last 5 quarters it ranged from $70K (Q4 2025) to $1.1M (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $706K | -35% | +817% |
| Q2 2026 | $1.1M | 15× | +756% |
| Q4 2025 | $70K | -9% | — |
| Q3 2025 | $77K | -39% | — |
| Q2 2025 | $126K | — | — |
Q3 2026 at a glance
Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Akebia Therapeutics' capital expenditures?
Akebia Therapeutics' capital expenditures were $706K in Q3 2026 (third quarter 2026), -35% from Q2 2026.
How has Akebia Therapeutics' capital expenditures changed?
Over the last 5 quarters it ranged from $70K (Q4 2025) to $1.1M (Q2 2026).